Scholarlink

Background <p>Nivolumab plus ipilimumab (NIVO + IPI) is a standard first-line therapy for intermediate-risk and poor-risk metastatic renal cell carcinoma (mRCC), but the long-term prognostic impact of prior primary tumor resection in this setting remains unclear.</p> Methods <p>We retrospectively reviewed patients with mRCC that received NIVO + IPI as first-line therapy at eight Japanese institutions between October 2015 and May 2022. Patients were stratified into groups according to timing of metastasis and prior primary tumor resection (cytoreductive nephrectomy; CN): a metachronous group, a synchronous/CN(+) group, and a synchronous/CN(−) group. Progression-free survival, overall survival, and tumor responses were compared among groups, with a median follow-up of 54 months.</p> Results <p>Among 135 eligible patients, 40 were classified into the metachronous group (30%), 37 into the synchronous/CN(+) group (27%), and 58 into the synchronous/CN(−) group (43%). Compared with the synchronous/CN(−) group, both the metachronous and synchronous/CN(+) groups exhibited significantly longer progression-free survival (median: 18 and 19 vs. 6 months, respectively; <i>P</i> &lt; 0.01) and overall survival (median: not reached and 52 vs. 22 months, respectively; <i>P</i> &lt; 0.01). In multivariable analysis, absence of prior primary site resection was independently associated with shorter progression-free survival (<i>P</i> = 0.02) and overall survival (<i>P</i> &lt; 0.01). Objective response and disease control rates were highest in the metachronous group and lowest in the synchronous/CN(−) group.</p> Conclusion <p>In this multicenter cohort with long-term follow-up, prior primary tumor resection was associated with favorable long-term outcomes in patients with mRCC treated with NIVO + IPI, irrespective of synchronous or metachronous metastasis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of prior primary tumor resection on long-term prognosis in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: a multicenter analysis

  • 期刊论文

  • 发表日期：

    2026年5月19日

查看全文
  • Shimpei Yamashita,
  • Shuzo Hamamoto,
  • Yukari Bando,
  • Shingo Toyoda,
  • Ryotaro Tomida,
  • Makito Miyake,
  • Noriyuki Ito,
  • Noriya Yamaguchi,
  • Junya Furukawa,
  • Kazutoshi Fujita,
  • Isao Hara,
  • Yasuo Kohjimoto

摘要

Background

Nivolumab plus ipilimumab (NIVO + IPI) is a standard first-line therapy for intermediate-risk and poor-risk metastatic renal cell carcinoma (mRCC), but the long-term prognostic impact of prior primary tumor resection in this setting remains unclear.

Methods

We retrospectively reviewed patients with mRCC that received NIVO + IPI as first-line therapy at eight Japanese institutions between October 2015 and May 2022. Patients were stratified into groups according to timing of metastasis and prior primary tumor resection (cytoreductive nephrectomy; CN): a metachronous group, a synchronous/CN(+) group, and a synchronous/CN(−) group. Progression-free survival, overall survival, and tumor responses were compared among groups, with a median follow-up of 54 months.

Results

Among 135 eligible patients, 40 were classified into the metachronous group (30%), 37 into the synchronous/CN(+) group (27%), and 58 into the synchronous/CN(−) group (43%). Compared with the synchronous/CN(−) group, both the metachronous and synchronous/CN(+) groups exhibited significantly longer progression-free survival (median: 18 and 19 vs. 6 months, respectively; P < 0.01) and overall survival (median: not reached and 52 vs. 22 months, respectively; P < 0.01). In multivariable analysis, absence of prior primary site resection was independently associated with shorter progression-free survival (P = 0.02) and overall survival (P < 0.01). Objective response and disease control rates were highest in the metachronous group and lowest in the synchronous/CN(−) group.

Conclusion

In this multicenter cohort with long-term follow-up, prior primary tumor resection was associated with favorable long-term outcomes in patients with mRCC treated with NIVO + IPI, irrespective of synchronous or metachronous metastasis.